The WSO Brain and hEart globAl iniTiative - STROKE (BEAT-STROKE) is a cluster randomized controlled trial, testing whether an educational and implementation Neurocardiology tool can improve adherence to best practice recommendations for secondary stroke prevention of cardioembolic strokes, as defined by the WSO Systematic Review and Synthesis of Global Stroke Guidelines or more recent high-quality evidence published after the last stroke guidelines1

开始日期2027-03-01

申办/合作机构

W. L. Gore & Associates, Inc.

[+1]

NCT07856238

/ Not yet recruitingN/A

Long-Term Effectiveness and Safety of Sacral Neuromodulation With InterStim for the Management of Lower Urinary Tract Dysfunction

This observational study will evaluate the long-term effectiveness, safety, and patient satisfaction associated with sacral neuromodulation using the InterStim™ system in adults treated for lower urinary tract dysfunction at Fundación Santa Fe de Bogotá. The study will include patients who underwent definitive InterStim implantation between January 2010 and June 2026 for conditions including overactive bladder, urgency urinary incontinence, non-obstructive acontractile detrusor, or non-obstructive urinary retention.
Clinical information before implantation, details of the procedure, complications, reinterventions, device replacements, and explantations will be obtained retrospectively from medical records. Patients who can be contacted will also complete a single telephone follow-up assessment to evaluate current urinary symptoms, perceived improvement, satisfaction with treatment, catheter use, and current device status.
The study aims to describe the long-term effectiveness and safety of InterStim therapy in a Colombian population, including changes in urinary incontinence, patient-reported improvement and satisfaction, complications, therapeutic failure, and device survival.

开始日期2026-12-01

申办/合作机构

Fundación Renal de Colombia

[+1]

NCT07769424

/ Not yet recruitingN/AIIT

Impact of Physiologic Pacemaker Programming on Cognitive Function and Health Status in Patients With Symptomatic Bradycardia

This proof-of-concept study will evaluate whether physiologic pacemaker programming improves cognitive function and health status in patients with symptomatic bradycardia who require permanent pacemaker implantation.
Participants will be randomized to either standard pacemaker programming at 60 beats per minute or individualized physiologic rate pacing between 60 and 90 beats per minute using the myPACE algorithm. Cognitive function and health status will be assessed before pacemaker implantation and again at the routine 3-month pacemaker clinic visit.
The primary outcome is change in Montreal Cognitive Assessment total score. The secondary outcome is change in SF-36 mental component summary score.

开始日期2026-12-01

申办/合作机构

University of Minnesota

[+1]

100 项与 Medtronic Plc 相关的临床结果

登录后查看更多信息

0 项与 Medtronic Plc 相关的专利（医药）

登录后查看更多信息

734

项与 Medtronic Plc 相关的文献（医药）

2026-10-01·HEART RHYTHM

Safety and performance of a novel defibrillation lead for left bundle branch area placement: Primary results of the LEADR LBBAP clinical trial

Article

作者: Zakaib, John S ; Vijayaraman, Pugazhendhi ; Afzal, Muhammad R ; Schloss, Edward J ; Geelen, Tessa ; Mason, Pamela K ; Denman, Russell ; Whinnett, Zachary I ; Platner, Megan L ; Pokharel, Parash ; Tanner, Jocelyn ; Burrell, James ; Jastrzębski, Marek ; Liu, Xingbin ; Crossley, George H ; Abhayaratna, Walter P ; Philippon, François ; Kron, Jordana ; Butler, Kiah

BACKGROUND:

Right ventricular placement of the OmniaSecure defibrillation lead has demonstrated high defibrillation success and low occurrence of lead-related major complications. With the advent of left bundle branch area pacing (LBBAP) as a physiological pacing option, the use of the OmniaSecure lead may be a viable alternative for LBBAP in the implantable cardioverter-defibrillator population.

OBJECTIVE:

This study aimed to understand the defibrillation efficacy at implant and the safety of the OmniaSecure lead for LBBAP.

METHODS:

The global Lead Evaluation for Defibrillation and Reliability LBBAP trial enrolled patients indicated for de novo implantation of a primary or secondary prevention implantable cardioverter-defibrillator or cardiac resynchronization therapy with a defibrillator. Per study protocol, LBBAP includes electrocardiographic characterization of left bundle branch pacing and deep septal pacing. The primary efficacy objective was defibrillation efficacy at implant exceeding a prespecified threshold of 88% in ≥160 patients. The primary safety endpoint was to demonstrate the OmniaSecure lead-related major complication rate at 3 months after implant.

RESULTS:

A total of 307 patients underwent an LBBAP implant attempt (age 64.9 ± 12.2 years; 28.7% female; body mass index 28.4 ± 6.1 kg/m²). A total of 293 patients were successfully implanted per protocol (95.4%). The primary efficacy objective was met with 100% of patients defibrillated to protocol. The observed freedom from OmniaSecure lead-related major complications at 3 months was 97.9% (95% confidence interval 95.8-100). There were zero study lead fractures, no oversensing adverse events, and stable electrical parameters through 2.6 ± 2.5 months' follow-up.

CONCLUSION:

These results demonstrate that implantation of OmniaSecure lead when intended for LBBAP results in high defibrillation success at implant, stable short-term electrical parameters, and a low rate of OmniaSecure lead-related major complications at 3 months.

2026-10-01·INDIAN JOURNAL OF PEDIATRICS

Device Usage Characteristics and Glycaemic Control in Indian Adolescents with Type-1 Diabetes Using the MiniMed™ 780G System

Letter

作者: Mondkar, Shruti ; Khadilkar, Anuradha ; Khadilkar, Vaman ; Srivastava, Niharika ; Bhade, Karishma ; Mukhekar, Vinaykumar

2026-09-22·EUROPEAN HEART JOURNAL

Atrial fibrillation density as a biomarker for ischaemic stroke risk prediction

Article

作者: Wang, Kaicheng ; Rosman, Lindsey ; Passman, Rod S ; Sarkar, Shantanu ; Ziegler, Paul D

Abstract:

Background and Aims:

Atrial fibrillation (AF) is frequently classified by episode duration and cumulative burden, yet these methods fail to characterize temporal episode distribution (AF density), which may be more clinically relevant and prognostically important. This study evaluated AF density’s association with ischaemic stroke and whether it improves risk stratification compared with AF burden.

Methods:

Data from two US cohorts with cardiac implantable electronic devices remotely monitored by the Veterans Health Administration and University of North Carolina (January 2010–May 2025) were analysed. AF burden (percentage of time in AF) and density [range: 0 (dispersed episodes) to 1 (consolidated episodes)] were assessed in 30-day intervals and categorized as low (>0–0.3), medium (>0.3–0.6), medium-high (>0.6–0.9), and high (>0.9–1.0). Patients with permanent AF or no episodes ≥6 min were excluded. G-formula modelling estimated 1-year stroke risk ratios (RRs), adjusting for baseline and time-varying covariates. Results were pooled using random-effects meta-analysis.

Results:

Of 41 780 patients, 12 868 met inclusion criteria (mean age 72.0 years; median CHA2DS2-VASc 4.0); 336 experienced ischaemic stroke over a median 4.0-year follow-up (6.3 per 1000 person-years). Atrial fibrillation density demonstrated a dose–response relationship with 1-year stroke risk (RR 1.75; 95% confidence interval 1.25–2.44) and findings were consistent across device types, comorbidities, age, and anticoagulation status. At each level of AF burden, patients with high density exhibited greater stroke risk.

Conclusions:

Atrial fibrillation density demonstrated robust dose–response relationships with ischaemic stroke independent of AF burden and enhanced risk stratification, suggesting that density may enable more precise stroke risk assessment and personalized prevention strategies.

4,037

项与 Medtronic Plc 相关的新闻（医药）

2026-10-10

·研界OmniSci

Chris Fang 博士加入维泰瑞隆，出任高级副总裁

2026年10月10日，全球化临床阶段生物科技公司维泰瑞隆（Sironax）宣布重要人事任命：Chris Fang 博士正式加入公司，担任高级副总裁（肥胖与代谢健康全球医学负责人），将进一步增强公司在肥胖及代谢疾病领域的临床开发与医学战略能力，并加速推进相关创新管线的全球开发进程。维泰瑞隆成立于 2017 年，由王晓东博士、张志远博士联合创立，聚焦神经退行性疾病、炎症免疫疾病、代谢疾病及罕见病领域。公司围绕衰老、神经损伤、炎症失调的核心机制搭建多元化研发管线，核心项目涵盖 SARM1 抑制剂、RIPK1 抑制剂、NAMPT 激动剂等，中美瑞澳多地布局。近年来公司管线捷报频传，多个候选药物进入临床阶段，部分项目获得 FDA 快速通道资格，同时完成与跨国药企的重要平台合作，业务快速发展的同时持续引进海内外资深产业人才，夯实管理与研发团队实力国际科技创。公司最近入选Fierce Biotech 2026年度“Fierce 15”榜单，获评最具创新力和发展前景的生物科技公司之一。 Chris Fang 博士是一位医师科学家，在生物技术、制药及医疗技术领域拥有超过25年的领导与管理经验。曾在礼来、强生和美敦力以及多家新兴生物技术和医疗技术公司担任高级管理职务。Fang博士曾领导多项从早期研发直至III期阶段的临床项目，其专业领域涵盖肥胖、心血管代谢和肝脏疾病、免疫学、神经科学以及传染病。他还曾领导数字健康和人工智能解决方案的开发，以加速药物开发进程。生物医药产业的竞争，本质是科学与人才的竞争。作为立足中国、面向全球的生物技术企业，维泰瑞隆一直坚持吸纳来自全球的产业与科研人才，搭建兼具国际视野与本土洞察力的复合型团队，覆盖药物发现、转化医学、临床开发、注册、商务等全链条能力。此次 Chris Fang 博士履新，是维泰瑞隆人才战略的又一重要落子。未来，团队将继续围绕 SARM1、RIPK1 等核心靶点，持续推进多项在研项目的全球临床研究，探索衰老相关疾病全新治疗手段，努力解决临床上大量尚未被满足的治疗需求。声明：本内容仅用作行业信息传播，为作者独立观点，不代表研界OmniSci立场，也不构成任何投资与医疗建议。如需转载，请务必注明文章作者与来源。 END 点击领取2026 CPHI思享会门票

2026-10-09

·心医讯

靶向心衰新机制！百洋首个自主孵化1类创新药YY524051获批临床

近日，百洋医药集团旗下心血管创新转化平台百洋智心宣布，其依托心血管疾病全国重点实验室转化的首个项目YY524051获得国家药品监督管理局药物临床试验批准，受理号CXHL2600901，拟开发用于射血分数保留的心力衰竭，后续将按获批方案启动I期临床研究。这一成果，也是白洋智心依托国家级实验室科研实力，成功落地转化的首个原创新药项目。靶点发现从JUN转录因子到药物干预此次获批的YY524051核心优势，源于心血管疾病全国重点实验室基于中国人组织样本率先发现的HFpEF关联靶点。研究显示，转录因子JUN在HFpEF中具有重要作用：在心肌细胞中过表达JUN可诱导与HFpEF相似的心脏舒张功能障碍及相关疾病表型，而对JUN进行干预则能够明显改善心脏舒张功能。围绕这一发现，团队进一步整合转录组、ChIP-seq及临床患者样本数据进行交叉验证，对JUN下游相关靶点进行系统筛选，最终确定了具有药物干预潜力的新靶点。临床背景心衰长期缺乏根源性治疗方案射血分数保留的心力衰竭是心衰的主要类型之一，约占全部心衰患者的一半。与射血分数降低的心衰不同，HFpEF的发病机制更为复杂，涉及心肌舒张功能障碍、炎症、纤维化等多个环节。现有临床药物仅能缓解患者水肿、气喘等表面症状，无法针对核心致病机制开展干预，难以阻止心脏功能持续衰退。多数患者需长期反复就医，预后状态较差，行业长期亟需全新靶点、全新机制的原创药物打破治疗僵局。 YY524051是百洋首个自主孵化的1类创新药，拟开发用于HFpEF，有望为这一疾病提供新的治疗选择。创新体系自主研发与投资孵化并行 YY524051是百洋智心首个全流程自主孵化、自主研发的1类创新药，标志着百洋医药彻底打通从靶点发现、机制验证、分子开发到临床转化的完整新药研发链路，实现了从医药商业化运营向源头创新研发的关键转型。此次临床获批，也印证了企业“产学研深度融合”创新模式的可行性与有效性。相较于传统引进、合作开发模式，该自研项目落地，让百洋医药在心衰高端创新药赛道拥有了自主知识产权的核心成果，填补了企业在HFpEF精准治疗领域的产品空白，为后续心血管创新药持续迭代奠定基础。目前，百洋已围绕心血管、肿瘤、抗器官纤维化及骨健康等领域持续推进创新药械布局。除心血管领域外，百洋投资孵化的创新成果还包括全球首个靶向整合素αvβ3的广谱肿瘤创新核药、中国首个自主研发的全磁悬浮人工心脏，以及全球领先的头颈部放射外科机器人、体部放射外科机器人等。抗肺纤维化创新药、骨再生创新药等项目也在持续推进。关于百洋医药百洋医药集团是一家以大健康产业为核心的综合性企业集团，业务覆盖医药商业化、创新药械研发与孵化、医疗服务等领域。百洋智心是其旗下专注于心血管前沿技术与创新转化的平台，依托心血管疾病全国重点实验室开展原创靶点发现与药物开发。本文来源：网络收集与整理。如有侵权，请联系作者删除。 ▷ 相关阅读 ◁ 推荐阅读行业动态 ✦新政新规｜✦企业IPO｜✦企业融资｜✦企业并购｜✦创新盘点创新企业 ✦美敦力｜✦爱德华｜✦雅培｜✦赛诺菲｜✦礼来｜✦诺和诺德｜✦波士顿科学｜✦强生｜✦飞利浦｜✦辉瑞｜✦拜耳｜✦核心医疗｜✦恒瑞医药｜✦石药集团｜✦ 默沙东｜✦ 诺华｜✦罗氏｜✦微创医疗｜✦健世科技｜✦ 歌礼制药｜✦ 华东医药｜✦ 启明医疗｜✦ 沛嘉医疗｜✦ 先健科技｜✦信达生物｜✦云顶新耀｜✦甘李药业｜✦科塞尔｜✦佰仁医疗新品获批 ✦获批NMPA/CDE｜✦获批FDA｜✦获批CE/MDR/EMA 长按二维码关注我们

2026-10-09

·国家药品监督管理局

柯惠有限责任公司Covidien llc对气管切开插管Tracheostomy Tubes主动召回（境外）

索引号JGXX-2026-10071主题分类监管信息 / 责令召回信息标题柯惠有限责任公司Covidien llc对气管切开插管Tracheostomy Tubes主动召回（境外）发布日期 2026-10-09　　柯惠医疗器材国际贸易（上海）有限公司报告，通过投诉监测发现，气管切开插管在使用过程中，其15 mm接头连接接口可能发生非预期分离。尽管气道仍可保持通畅，但该分离可能中断气管切开插管与呼吸支持设备（包括呼吸机及呼吸回路）之间的连接，若未能及时识别并处理，可能对患者治疗造成不利影响。柯惠有限责任公司Covidien llc对其生产的气管切开插管Tracheostomy Tubes（国械注进20162080971）主动召回。召回级别为一级召回。涉及产品的型号、规格及批次等详细信息见《医疗器械召回事件报告表》。　　　　　　附件：医疗器械召回事件报告表　　2026年10月9日柯惠医疗器材国际贸易（上海）有限公司召回报表.pdf

100 项与 Medtronic Plc 相关的药物交易

登录后查看更多信息

100 项与 Medtronic Plc 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2026年10月20日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床2期

批准上市

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

阿法地博特明 ( BMPR1A )	胫骨骨折更多	批准上市
糠酸莫米松 ( GR )	慢性鼻窦炎伴鼻息肉更多	批准上市
佐他莫司 ( mTOR )	冠状动脉再狭窄更多	批准上市
六氯酚	革兰氏阳性细菌感染更多	批准上市
Atrial natriuretic factor prohormone 31-67(Madeleine Pharmaceuticals) ( NPR )	心脏衰竭更多	临床2期